This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Agitation in nursing home residents with dementia (VIDEANT trial): effects of a cluster-randomized, controlled, guideline implementation trial
Rapp, Michael A.,
Mell, Thomas,
Majić, Tomislav,
Treusch, Yvonne,
Nordheim, Johanna,
Niemann-Mirmehdi, Mechthild,
Gutzmann, Hans,
Heinz, Andreas
Objective: To test the effect of a complex guideline-based intervention on agitation and psychotropic prescriptions.; Design, Setting, Participants: Cluster randomized controlled trial (VIDEANT) with blinded assessment of outcome in 18 nursing homes in Berlin, Germany, comprising 304 dementia patients.; Intervention: Training, support, and activity therapy intervention, delivered at the level of each nursing home, focusing […]
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial
Prieto-Alhambra, D.,
Judge, A.,
Arden, N. K.,
Cooper, C.,
Lyles, K. W.,
Javaid, M. K.
Unlabelled: Patients with cognitive impairment (CI) often do not receive secondary fracture prevention. Use of zoledronic acid led to a similar reduction in re-fracture risk but the survival benefit was limited to those without CI.; Introduction: We tested whether the effects of id (Zol) on re-frazoledronic accture and mortality differed in patients presenting with a […]
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
Porsteinsson, Anton P.,
Drye, Lea T.,
Pollock, Bruce G.,
Devanand, D. P.,
Frangakis, Constantine,
Ismail, Zahinoor,
Marano, Christopher,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Pelton, Gregory,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Shade, David M.,
Weintraub, Daniel,
Yesavage, Jerome,
Lyketsos, Constantine G.
Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]
Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET
Peters, Ruth,
Beckett, Nigel,
Fagard, Robert,
Thijs, Lutgarde,
Wang, Ji-Guang,
Forette, Francoise,
Pereira, Lisa,
Fletcher, Astrid,
Bulpitt, Christopher
Objectives: High blood pressure (BP) has been associated with increased risk of dementia. Concerns have been raised about lowering BP too far in the very elderly and thereby increasing risk. There is some evidence to suggest a potential ‘J’-shaped relationship between DBP and risk of cognitive impairment. This was investigated using data from the HYpertension […]
Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors
Pariente, A.,
Fourrier-Reglat, A.,
Bazin, F.,
Ducruet, T.,
Dartigues, J. F.,
Dragomir, A.,
Perreault, S.,
Moore, N.,
Moride, Y.
Objective: To determine the effect of treatment gaps on the risk of institutionalization or death among community-dwelling elderly patients treated with cholinesterase inhibitors (ChIs).; Methods: A survival analysis was conducted among a cohort of community-dwelling elderly patients (age 66+) newly treated with ChIs identified in the Quebec drug claims databases (Régie de l’Assurance Maladie du […]
Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer’s disease
Okahara, Kazunori,
Ishida, Yasushi,
Hayashi, Yoshihito,
Inoue, Teruhiko,
Tsuruta, Kazuhito,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Yoshida, Kensei,
Noda, Shouji,
Tomita, Seiichiro,
Fujimoto, Masumi,
Hosomi, Jun,
Mitsuyama, Yoshio
Yokukansan (YKS) is used frequently against behavioral and psychological symptoms of dementia (BPSD) together with donepezil in patients with Alzheimer’s disease (AD). Here, we investigated the efficacy and safety of YKS in patients with AD in a non-blinded, randomized, parallel-group comparison study. Patients who had at least one symptom score of four or more on […]
The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer’s disease
Ohnishi, Takashi,
Sakiyama, Yojiro,
Okuri, Yuichi,
Kimura, Yuji,
Sugiyama, Nami,
Saito, Takayuki,
Takahashi, Masayoshi,
Kobayashi, Takumi
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized, double-blind, placebo controlled trial to […]
Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer’s disease
O'Caoimh, Rónán,
Healy, Liam,
Gao, Yang,
Svendrovski, Anton,
Kerins, David M.,
Eustace, Joseph,
Kehoe, Patrick Gavin,
Guyatt, Gordon,
Molloy, D. William
Background: Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may also improve exercise tolerance in functionally impaired older adults with normal cognition, suggesting that CACE-Is may positively influence activities of daily living (ADL) in dementia.; Objective: To compare rates of decline in patients […]